LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Geschlossen

BrancheGesundheitswesen

0.2

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.2

Max

0.21

Schlüsselkennzahlen
By Trading Economics
Einkommen	574K -47M
Verkäufe	3.2M 17M
EPS	-0.2
Gewinnspanne	-275.223
Angestellte	161
EBITDA	947K -45M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+2433.33% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 45M
Vorheriger Eröffnungskurs	0.2
Vorheriger Schlusskurs	0.2

Nachrichtenstimmung

By Acuity

81%

19%

319 / 345 Ranking in Healthcare

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

25. Mai 2026, 08:24 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. Mai 2026, 21:22 UTC

Ergebnisse

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. Mai 2026, 20:50 UTC

Market Talk

Ergebnisse

Basic Materials Roundup: Market Talk

25. Mai 2026, 16:20 UTC

Market Talk

Ergebnisse

Basic Materials Roundup: Market Talk

25. Mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. Mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. Mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. Mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. Mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. Mai 2026, 12:56 UTC

Market Talk

Ergebnisse

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. Mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. Mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. Mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. Mai 2026, 12:10 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Delivery Hero's Assets Look Strategic -- Market Talk

25. Mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. Mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. Mai 2026, 10:05 UTC

Ergebnisse

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. Mai 2026, 10:04 UTC

Ergebnisse

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. Mai 2026, 10:03 UTC

Ergebnisse

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. Mai 2026, 10:02 UTC

Ergebnisse

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. Mai 2026, 10:01 UTC

Ergebnisse

Tenaga Nasional 1Q Net Up 3.7% on Year

25. Mai 2026, 10:00 UTC

Ergebnisse

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q EPS MYR0.1883

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q Rev MYR17.1B

25. Mai 2026, 09:56 UTC

Ergebnisse

Tenaga Nasional 1Q Net MYR1.1B

25. Mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. Mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. Mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. Mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

2433.33% Vorteil

12-Monats-Prognose

Durchschnitt 5.32 USD 2433.33%

Hoch 15 USD

Tief 0.28 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Stimmung

By Acuity

319 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.